Hyaluronidase-zzxf/Pertuzumab/Trastuzumab

DRUG3 trials

Conditions

Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8

Early Phase 1

SMMART Adaptive Clinical Treatment (ACT) Trial

WithdrawnNCT05238831

OHSU Knight Cancer InstituteAdvanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma +14

Start: 2023-01-30End: 2026-05-31Updated: 2024-01-23

Phase 2

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

CompletedNCT05730712

Mayo ClinicCastration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2024-03-08End: 2025-04-10Updated: 2026-06-09

Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

RecruitingNCT05256225

National Cancer Institute (NCI)Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma +5

Start: 2022-11-16End: 2027-10-31Target: 360Updated: 2026-09-18

Related Papers

Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).